The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial - KCT23/2022-ZOOM-IN

Start Date26 May 2025

Sponsor / Collaborator

KRKA dd

NCT06917118

/ Not yet recruitingNot ApplicableIIT

Multimodal Pain Management After Wide Awake Local Anesthesia No Tourniquet Orthopedic Hand Surgery: A Randomized Control Trial

The main objective of the study is to measure the efficacy of a multimodal postoperative pain regimen consisting of oral acetaminophen and naproxen compared to a traditional opioid-only pain regimen following elective wide awake local anesthesia no tourniquet (WALANT) hand surgery in a Hispanic population. The study is a randomized control trial comparing the clinical outcomes of patients undergoing elective WALANT hand surgery performed by a board-certified, fellowship-trained orthopedic hand surgeon (Dr. Christian A. Foy).
The study groups are:
* Control group: standard pain control with opioids
* Experimental group: multimodal non-opioid pain control
Study Outcomes are:
* VAS pain scores (7 days),
* Total opioid usage
* Patient satisfaction
* Adverse events
We hypothesize that patients receiving multimodal pain regimens will report lower opioid use, lower pain scores, and greater satisfaction than patients receiving traditional opioid-only pain management.

Start Date01 May 2025

Sponsor / Collaborator

University of Puerto Rico

NCT06861920

/ RecruitingPhase 4

Targeting Interindividual Variability in NSAID Responses to Mitigate Chronic Pelvic Pain Risk in Dysmenorrhea (NSAID HEAL)

The goal of this clinical trial is to learn if NSAIDs (i.e. naproxen sodium) can treat menstrual pain and prevent the development of chronic pelvic pain in menstruating adults with painful periods. The main questions it aims to answer are:
* Can non-menstrual pelvic pain reduction be predicted by menstrual pain response to NSAIDs?
* Will participants with the largest reductions in multi-site sensitivity following NSAID therapy have the largest reductions in non-menstrual pelvic pain?
Researchers will compare naproxen sodium to a placebo (a look-alike substance that contains no drug) to see if naproxen sodium works to treat painful periods.
Participants will:
* Take naproxen sodium or placebo during several days of their menstrual period every month for 1 year.
* Complete computer questionnaires and tests from home every 3 months.
* Complete at-home urine tests to measure hormones every few days for 1-year.
* Use a pin-prick to collect a small spot of blood, and use a pad or tampon to collect a sample of menstrual blood, and bring it to the research site twice over a 1-year period.
* Come to the research site twice over a 1-year period to complete sensory assessments and undergo a blood draw.
The major goal of the study is to develop a multivariable statistical model (see https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-021.html ) describing the factors that effectiveness of pain medication and risk for chronic pain

Start Date07 Apr 2025

Sponsor / Collaborator

Endeavor Health

[+2]

100 Clinical Results associated with Naproxen

100 Translational Medicine associated with Naproxen

100 Patents (Medical) associated with Naproxen

14,071

Literatures (Medical) associated with Naproxen

01 Jan 2026·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Enhanced peroxymonosulfate activation through visible-light-responsive ultrathin phosphorus–iron-codoped g-C3N4 nanosheets for efficient naproxen degradation

Article

Author: Huang, Jiaxing ; Tu, Ningyu ; Liang, Qianwei ; Zhong, Xiaojun ; Yu, Xiaolong ; Xue, Qiao ; Zhong, Jiapeng ; Sun, Jianteng ; Zhong, Ke ; Yao, Ruipu

An efficient photocatalyst was constructed via a simple single-stage thermal condensation reaction and applied to photoinduced peroxymonosulfate (PMS) activation for naproxen (NPX) degradation. Batch experiments demonstrated that phosphorus (P)-iron (Fe)-codoped g-C₃N₄ (PFeCN) exhibited superior catalytic performance compared to previously reported catalysts, achieving 97 % NPX degradation within 20 min and a reaction rate constant approximately tenfold higher than that of pristine g-C₃N₄. PFe codoping increased active site exposure, improved charge carrier separation efficiency, and enhanced light absorption capacity. Specifically, PN sites served as adsorption and activation centers for PMS, while Fe doping alleviated the reduction in specific surface area caused by P doping and further enhanced photoelectrochemical properties. Radical species analysis confirmed superoxide radicals as the dominant reactive species. The degradation pathways and toxicity evolution of NPX were also investigated, providing critical insights for environmental risk assessment. Furthermore, PFeCN maintained robust catalytic performance under various environmental conditions and after multiple cycles, indicating strong application prospects. This study offers key perspectives on the rational design of heteroatom-doped photocatalysts through atomic-level engineering for efficient photoinduced PMS activation.

01 Jan 2026·BIORESOURCE TECHNOLOGY

Superoxide-derived singlet oxygen generation via electron transfer-mediated activation of persulfate by heterogeneous biochar catalysts for naproxen degradation: Effects of aromatization degree on electron exchange capacity

Article

Author: Shin, Jaegwan ; Kim, Young Mo ; Rho, Hojung ; Chon, Kangmin

In this study, heterogeneous biochar catalysts derived from spent coffee grounds (HCBCs) and walnut shells (HWBCs) were synthesized at three pyrolysis temperatures (500 °C (HCBC500, HWBC500), 650 °C (HCBC650, HWBC650), and 800 °C (HCBC800, HWBC800)) to elucidate effects of changes in the aromatization degree determining electron exchange capacity (EEC) of heterogeneous biochar catalysts on the degradation of naproxen (NPX) via the electron transfer-mediated activation of peroxydisulfate (PDS). The greater EEC values of highly aromatic HCBCs and HWBCs produced at higher pyrolysis temperatures led to increased degradation efficiencies of NPX by the HCBCs/PDS and HWBCs/PDS systems. The HCBC800/PDS system achieved the highest degradation efficiency of NPX, at 80.9%, compared to 16.4-48.1% for other systems. These observations highlight that the EEC relying on the aromatization degree of heterogeneous biochar catalysts is a key factor governing the degradation of NPX via the electron transfer-mediated activation of PDS. In the HCBC800/PDS system, electrophilic decarboxylation induced by superoxide-derived singlet oxygen was mainly responsible for the degradation of NPX rather than hydroxyl radical-driven electrophilic hydroxylation. Moreover, the HCBC800/PDS system exhibited excellent reuse efficiency (≥73.2%) for the degradation of NPX over four consecutive cycles. Although increases in bioaccumulation potential and mutagenicity were detected for some degradation intermediates of NPX produced via the HCBC800/PDS system, most of them were less harmful to aquatic ecosystems. Therefore, HCBC800 could be a promising option as a carbonaceous material-based heterogeneous catalyst to activate PDS via the electron transfer for eliminating NPX.

01 Dec 2025·WATER RESEARCH

Flow-driven biomarker movement in gravitational sewers for wastewater-based epidemiology and public health monitoring

Article

Author: Shuttleworth, Joe ; Bailey, Olivia ; Elliss, Harry ; Kevill, Jessica L ; Proctor, Kit ; Farkas, Kata ; Jones, Davey L ; Kasprzyk-Hordern, Barbara

The movement of biological (genetic viral, fungal or bacterial) and chemical indicators (BCIs) within sewer networks is critical to wastewater-based epidemiology (WBE) enabling accurate calculation of chemical and pathogen loads within a community. These quantified BCIs, which include genetic material from pathogens as well as pharmaceuticals, from a range of classes, serve as proxies for community-wide health and behaviour patterns. However, a critical knowledge gap exists in understanding how different BCIs move within complex sewer systems, which could lead to misinterpretation of community-level data. This study aims to address this gap by investigating the transport behaviour of 5 common BCIs (carbamazepine, metoprolol, naproxen, venlafaxine and PMMoV) in a real-world gravitational sewer network. In addition, we also spiked the wastewater with deuterated caffeine-d9, allowing discrimination from native caffeine present in the network and therefore, enabling an accurate assessment of recovery due to no public use. Our results revealed that all targets travelled with limited dispersion throughout the first stage of the gravitational sewer, 0.8 km after introduction into the network. It was observed that carbamazepine (logD = 2.8 at sewer pH), exhibited more dispersion throughout the remaining 2.3 km of the gravitational system, showing a broader, more asymmetric trace with increased tailing, which potentially indicates sorption to the solid phase, impacting its movement through the network. All other chemical targets had similar movement patterns, indicating a lower tendency to bind to the solid phase (logD < 1, at average sewer pH). Loads were calculated using dye-predicted flow rates and normalized to caffeine-d9. Carbamazepine loads were under-predicted by 74 %, attributed to losses to the solid phase throughout the sewer system. Conversely, metoprolol, naproxen, and venlafaxine loads were over-predicted (146 %, 32 %, and 129 %, respectively), likely due to additional public inputs. Our results demonstrate that more hydrophilic chemicals move throughout the sewer network with limited dispersion while hydrophobic compounds may experience significant losses. These findings have important implications for the accurate interpretation of WBE data, future BCI tracing studies and the selection of appropriate chemical markers for community health monitoring.

News (Medical) associated with Naproxen

05 Jun 2025

·pipelinereview.com

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 ( https://bpsasm.org/ ) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: “ The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain. ” The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain. Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo’s FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks. Professor O’Sullivan stated, “ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.” Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain. OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases. About ART26.12 ART26.12, Artelo’s lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio. SOURCE: Artelo Biosciences

Phase 1Clinical Result

12 Mar 2025

·www.prnewswire.com

Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As competition intensifies, these biosimilars are reshaping treatment choices and driving a shift in the market landscape. LAS VEGAS, March 12, 2025 /PRNewswire/ -- Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more prevalent in Europe and North America than in Asia and South America. In patients with psoriasis, the prevalence of psoriatic arthritis can range from 6% to 34% in Western populations. Despite its impact, many individuals with psoriatic arthritis remain undiagnosed or receive inadequate treatment, highlighting the need for increased awareness and access to specialized care. As per DelveInsight analysis, among the 7MM, the United States accounted for the highest number of prevalent cases of psoriatic arthritis in 2023, and these cases are expected to increase by the end of 2034 due to several key factors such as an increase in awareness and diagnosis, as well as the rapid prevalence of PsA. Psoriatic arthritis, occurring in approximately 20% of individuals with psoriasis, is a chronic inflammatory arthritis intricately linked to psoriatic arthritis. This aggressive condition is characterized by potential significant morbidity and compromised quality of life. Treatment approaches for psoriatic arthritis encompass a variety of strategies aimed at managing symptoms, slowing disease progression, and improving the overall quality of life. These approaches typically involve a combination of pharmacological therapies, lifestyle modifications, and, in severe cases, surgical interventions. Psoriatic arthritis treatment is highly individualized based on disease severity, response to therapy, and patient preferences, with multidisciplinary care from rheumatologists, dermatologists, and physical therapists playing a key role. Pharmacological treatment for psoriatic arthritis primarily targets inflammation and pain relief. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are often the first line of defense, helping to reduce pain and inflammation. Disease-modifying antirheumatic drugs (DMARDs) like methotrexate, sulfasalazine, and leflunomide are commonly prescribed to prevent joint damage and suppress the inflammatory process. For individuals with mild-to-moderate psoriatic arthritis, oral small molecules (OSMs) like OTEZLA (apremilast) offer a convenient, non-injectable option by modulating inflammatory pathways. Biologic agents have revolutionized the treatment landscape for psoriatic arthritis. These medications specifically inhibit key molecules in the inflammatory cascade. TNF inhibitors like HUMIRA (adalimumab), ENBREL (etanercept), and REMICADE (infliximab) are frontline biologics that target tumor necrosis factor, a crucial driver of inflammation. Patients who do not respond to TNF inhibitors may benefit from IL-17 inhibitors like COSENTYX (secukinumab) and TALTZ (ixekizumab) or IL-12/23 inhibitors such as STELARA (ustekinumab). Learn more about the FDA-approved psoriatic arthritis drugs @ Drugs for Psoriatic Arthritis Treatment SKYRIZI (risankizumab), developed by AbbVie, is a humanized IgG1 monoclonal antibody that acts as an interleukin-23 (IL-23) antagonist. It can be used on its own or in conjunction with non-biologic DMARDs. In June 2022, the FDA approved SKYRIZI as the first and only targeted IL-23 inhibitor for adults with active psoriatic arthritis. Another biologic, TREMFYA (guselkumab by Janssen), was approved by the FDA in July 2020 as the first monoclonal antibody that selectively binds to the p19 subunit of IL-23, further expanding treatment options for psoriatic arthritis patients. BIMZELX (bimekizumab), developed by UCB Biopharma, is a humanized monoclonal antibody that targets IL-17A and IL-17F. It received European Commission approval in June 2023 for adults with active psoriatic arthritis and axial spondyloarthritis. On September 23, 2024, the FDA approved BIMZELX for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis (nr-axSpA) with objective inflammation, and active ankylosing spondylitis. In Phase III studies, BIMZELX showed meaningful responses in patients with inadequate TNF inhibitor responses and those new to biologics, indicating its potential as an important treatment option for psoriatic arthritis. In cases where joint damage becomes severe and unresponsive to medical therapies, surgical interventions like joint replacement surgery may be necessary to restore function and alleviate pain. Lifestyle changes, such as regular exercise, joint protection techniques, and weight management, are also critical in managing psoriatic arthritis, as excess weight can worsen symptoms and increase disease severity. The treatment landscape for psoriatic arthritis continues to evolve, offering hope to patients with more targeted therapies and improved outcomes. As companies like UCB Biopharma, AbbVie, and Janssen advance their biologic portfolios, the future looks promising for psoriatic arthritis management. The competition in the biosimilar market is intensifying as companies introduce cost-effective alternatives to blockbuster biologics. In December 2024, Celltrion announced FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis. Simultaneously, Biocon Biologics Ltd. is strengthening its position with positive Phase III results for YESINTEK, its biosimilar to ustekinumab, in adult patients with moderate to severe chronic plaque psoriasis. The pivotal randomized, double-blind, parallel-group study demonstrated comparable efficacy and safety to the reference biologic, STELARA, and the findings are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. With the approval of STEQEYMA and the promising clinical outcomes for YESINTEK, these biosimilars are poised to challenge STELARA by offering cost-effective alternatives in key immunology indications. As pricing pressures and healthcare sustainability concerns drive the demand for biosimilars, these developments mark a significant shift in the treatment landscape, providing greater accessibility and affordability for patients while increasing competition in the immunology market. To know more about psoriatic arthritis treatment options, visit @ New Treatment for Psoriatic Arthritis The psoriatic arthritis market is buzzing with numerous companies advancing treatments to cater to the growing patient base. Several therapies are expected to enter the market during the forecast period, providing new hope for patients. Some of these potential therapies include ACELYRIN Inc.'s Izokibep, Novartis Pharmaceuticals' Secukinumab, UCB Biopharma SRL's Bimekizumab, and Bristol-Myers Squibb's Deucravacitinib. Additionally, AbbVie's Upadacitinib and Risankizumab, as well as Eli Lilly and Company's Ixekizumab, are also part of the promising pipeline. Other noteworthy therapies include Sun Pharma's ILUMYA/ILUMETRI, Bristol-Myers Squibb's SOTYKTU, and Affibody's Izokibep in collaboration with Acelyrin and Inmagene. With these advancements, the psoriatic arthritis treatment landscape is set for a major shift, offering patients more tailored and effective options. The companies involved in developing biosimilars include Alvotech, Teva, Biocon Biologics, Celltrion, Fresenius Kabi, and others. Discover which therapies are expected to grab major psoriatic arthritis market share @ Psoriatic Arthritis Market Report ILUMYA/ILUMETRI by Sun Pharma is an interleukin-23 (IL-23) inhibitor classified as a humanized, anti-IL-23p19 monoclonal antibody. It works by blocking inflammatory proteins (cytokines and chemokines) in the body. By inhibiting the effects of IL-23, ILUMYA helps control the release of other inflammatory proteins, including IL-17 and TNF-α. This mechanism reduces inflammation, decreases the number of inflammatory cells in psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. The drug is currently undergoing evaluation in Phase III clinical development, actively recruiting subjects with active psoriatic arthritis who have prior exposure to anti-TNF agents, as well as those who are anti-TNF naïve. SOTYKTU, developed by Bristol-Myers Squibb, is the first and only novel oral selective tyrosine kinase 2 (TYK2) inhibitor being studied across multiple immune-mediated diseases. Deucravacitinib binds to the regulatory domain of the TYK2 enzyme, inhibiting its activation. This selective inhibition reduces the release of proinflammatory cytokines and chemokines, helping to control the inflammation associated with psoriatic arthritis and alleviating its signs and symptoms. Currently, the drug is being investigated for the treatment of psoriatic arthritis in a Phase III clinical trial. Izokibep, developed by Affibody in partnership with Acelyrin and Inmagene, is a unique antibody mimetic and a novel bispecific agent that potentially targets both subunits of the IL-17A homo-dimer and serum albumin. Affibody has entered into a partnership agreement with Acelyrin for the development and commercialization of izokibep and has completed a Phase II trial. As part of this agreement, Acelyrin obtained worldwide rights to izokibep, excluding selected Asian countries, where rights have been granted to Inmagene Biopharmaceuticals. In March 2024, Acelyrin announced the release of positive top-line results from the Phase IIb/III trial, indicating that izokibep was well-tolerated with a favorable safety profile. This drug is currently in Phase III clinical trial. Discover more about drugs for psoriatic arthritis in development @ Psoriatic Arthritis Clinical Trials The anticipated launch of these emerging therapies for psoriatic arthritis is poised to transform the market landscape in the coming years. As these cutting-edge treatments continue to mature and gain regulatory approval, they are expected to reshape the psoriatic arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the psoriatic arthritis market size was USD 9 billion in 2021 and is expected to grow significantly in the coming years. This growth can be attributed to the introduction of upcoming therapies and the rising prevalence of the condition. The anticipated launch of these therapies is also expected to attract new entrants to the psoriatic arthritis market, resulting in increased competition and innovation. DelveInsight's latest published market report titled " Psoriatic Arthritis Market Insight, Epidemiology, and Market Forecast – 2034" will help you discover which market leader is set to capture the largest market share. The report provides comprehensive insights into country-specific treatment guidelines, patient pool analysis, and epidemiology forecasts to help understand key opportunities and assess the market's underlying potential. The psoriatic arthritis market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Psoriatic Arthritis Total Diagnosed Prevalent Cases of Psoriatic Arthritis Gender-specific Diagnosed Prevalent Cases of Psoriatic Arthritis Severity-specific Diagnosed Prevalent Cases of Psoriatic Arthritis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Psoriatic Arthritis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this psoriatic arthritis market report to assess the epidemiology forecasts, understand patient journeys, gain insights into KOLs' opinions about upcoming treatment paradigms, and identify the factors contributing to changes in the psoriatic arthritis market. Additionally, stay informed about the mitigating factors that can enhance your market position in the psoriatic arthritis therapeutic space. Related Reports Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Affibody, Kymera, Selection Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, ACELYRIN Inc., among others. Psoriatic Arthritis Epidemiology Forecast Psoriatic Arthritis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Psoriatic Arthritis epidemiology trends. Ankylosing Spondylitis Market Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ankylosing Spondylitis companies, including UCB, AbbVie, Pfizer, Astella, Amgen, Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, among others. Psoriasis Market Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Psoriasis companies, including Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalClinical ResultPhase 2

04 Mar 2025

·www.fiercepharma.com

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug

Glenmark Pharma is recalling nearly 1.5 million bottles of the attention-deficit/hyperactivity disorder drug atomoxetin. Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has issued another. This time, the product pull covers about 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine.Eli Lilly previously sold the branded version of the drug, Strattera, but discontinued all strengths in 2023 after the arrival of generics.Unlike stimulant-based drugs that make up the bulk of ADHD treatment, including those like Vyvanse and Adderall, atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI).The recall was triggered by the presence of unacceptable levels of N-nitroso atomoxetine, a possible carcinogen, in multiple Glenmark atomoxetine batches, according to the FDA. The voluntary pull, which began Jan. 29, covers bottles of the drug in strengths ranging from 10 mg to 100 mg, the FDA said on its Enforcement Report webpage. The ADHD drugs were manufactured in Glenmark’s facility in Goa, India, and were distributed nationwide. Glenmark has weathered a string of recalls in recent years due to both manufacturing and labelling issues.In June 2024, the company recalled 114 batches of 750 mg potassium chloride extended-release capsules—or roughly 47 million capsules—over concerns that they failed to dissolve properly.In December, the company recalled 90,528 bottles of the high blood pressure drug diltiazem hydrochloride in tablet and extended-release forms due to unacceptable levels of another N-nitroso compound, N-nitroso-Desmethyl-Diltiazem.In separate actions in 2023, Glemark recalled 1,200 bottles of trandolapril and verapamil hydrochloride extended-release tablets used to treat high blood pressure; 37,200 bottles of Indomethacin, which is a non-steroidal anti-inflammatory used to treat pain and arthritis symptoms; and five lots (no bottle count provided) of Naproxen that is used to reduce fever or relieve mild pain.The previous year it recalled 98,307 packs of mometasone furoate topical solution, a corticosteroid lotion that treats skin conditions such as eczema, psoriasis, allergies and rash.

Clinical Result

100 Deals associated with Naproxen

External Link

KEGG	Wiki	ATC	Drug Bank
D00118	Naproxen	G02CC02 M01AE02 M02AA12	DB00788

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1983
Gout	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1982
Analgesia	Japan	Nipro ES Pharma KK	24 Jan 1978
Inflammation	Japan	Nipro ES Pharma KK	24 Jan 1978
Ankylosing Spondylitis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Juvenile Idiopathic Arthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Osteoarthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Rheumatoid Arthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	-	Targeted Medical Pharma, Inc.	01 Feb 2009
Toothache	Phase 2	United States	Iroko Pharmaceuticals LLC	01 Oct 2010
Peptic Ulcer	Phase 1	United Kingdom	Oxford Pharmascience Ltd.	01 May 2015
Rheumatic Diseases	Phase 1	United Kingdom	Oxford Pharmascience Ltd.	01 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2025	Not Applicable	Axial Spondyloarthritis	30	Celecoxib	ypbdjowtrw(fxoprwrqtc) = Adverse events were infrequent and mild across all NSAIDs, with only one serious adverse event (diarrhea) reported. mrzqotdvtg (ydwtefytdt ) View more	Positive	24 Oct 2025
				Meloxicam
NCT03771612 (CTgov)	Early Phase 1	Inflammation	144	Naproxen (Naproxen)	axsaebknlm(gebpzvocla) = miclxzyvls cblesntnaw (ilmtexyozq, 10) View more	-	25 Feb 2025
				Placebos (Placebo)	axsaebknlm(gebpzvocla) = ofivohcrlo cblesntnaw (ilmtexyozq, 10.5) View more
NCT05026320 (CTgov)	Phase 2	Contusions \| Soft Tissue Injuries	76	Placebo gel	ngdueeknld(maobrzcllq) = htxtmfqceb cuqrjacbty (nifesbmska, nnvlpbudir - fplcgqwcot) View more	-	22 Jan 2025
NCT02451748 (CTgov)	Phase 4	Rheumatoid Arthritis	32	Lab Work (DMARD's Responder and Non-Responder)	xvpsuzedkj(ghkznsusco) = lwtnafllwq unptinfozq (bfckpqfpbg, jadwgakybv - yfqaqbbhzx) View more	-	10 Jul 2024
				Naproxen+Medrol+Hydroxychloroquine+humira+prednisone+Lab Work+Triamcinolone+Methotrexate+Sulfasalazine+CDP870+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol))	lugmlpwtwm(bnamvfzxrr) = sgxlbiwiiu popkcrrklc (rcgtvtngat, 0.132) View more
NCT03347929 (Pubmed \| Pain) Manual	Phase 4	Sciatica	123	Naproxen 500 mg	qyhnorpxlc(znftaqayhj) = pcnxbwvxpo hjzqsqquxs (knwybzfgox ) View more	Negative	04 Jun 2024
				Placebo	-
NCT04694300 (CTgov)	Phase 4	Mouth and Tooth Diseases \| Acute Pain	30	Tramadol+Naproxen (Naproxen Sodium)	kcnctarswx(atqjmmiyup) = uhfmsfenkc xdrgiohney (dvfpwamwci, vmlqdkogfy - ilguouvfqf) View more	-	16 May 2024
				Tramadol+Acetaminophen (Acetaminophen)	kcnctarswx(atqjmmiyup) = yattbyfxlj xdrgiohney (dvfpwamwci, ewvigftspg - ekiywwuvog) View more
NCT02502006 (CTgov)	Phase 1	-	16	Celecoxib (Celecoxib)	fjmnlaxjpb(bkuwcxxkmq) = yeztresqsi sbpmxzsblg (nyotjwzgju, 1357) View more	-	13 Dec 2023
				Naproxen (Naproxen)	fjmnlaxjpb(bkuwcxxkmq) = ijwcouzxkm sbpmxzsblg (nyotjwzgju, 66.8) View more
NCT03697720 (CTgov)	Phase 4	Dysmenorrhea \| Bladder pain	26	Naproxen	svazrmscut(lmmiyhlhap) = iyfqppxein rujixrlwpr (ibonirtgps, 2.4) View more	-	18 Oct 2023
NCT00346216 (PRECISION, Pubmed \| Eur Heart J Cardiovasc Pharmacother)	Phase 4	Arthritis	24,081	Celecoxib	buaigzunok(yznetldpsw) = pnwijuayiz nqttdpjigl (ucdyevshtw )	Positive	02 Mar 2022
				Ibuprofen	buaigzunok(yznetldpsw) = jlvagcxepl nqttdpjigl (ucdyevshtw )
NCT00826462 (CTgov)	Phase 4	Tennis Elbow	177	Naprosyn (Control Group: Wait-and-see Treatment)	blwtsflagy = fpkvwxshvp tcrdetnbes (hjfhxejczv, ysjfzwnzcd - fznnrhglhs) View more	-	24 Jan 2022
				Placebo (Placebo Injection in Combination With Physical Therapy)	blwtsflagy = lgztyxwtdl tcrdetnbes (hjfhxejczv, mphtjvmwqm - fkxppexxie) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis